Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as a prominent treatment for T2DM with a notable weight loss effect via delayed gastric emptying, glucagon inhibition and stimulation of central receptors that modulate appetite suppression and energy expenditure [3, 4]. This evidence concerns the gene GCG and type 2 diabetes mellitus.